Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of Onradivir (ZSP1273) in Healthy Chinese Subjects
NCT03679143Phase 1Completed
- Sponsor
- Zhongsheng Pharma
- Start
- Sep 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anlatrelvir in Influenza A (IAV) (10 arms), sponsored by Zhongsheng Pharma. Primary endpoint: Number and severity of treatment-emergent adverse events and Serious Adverse Events. Started Sep 2018; status: completed.
02
Drugs
anlatrelvir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT03679143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03679143.